Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)

Table 3 Immunological Assays

	Biomaterial
Assay	PBMC¹	PB Immune cells²	CSF²
Flow cytometric assessment of CD49d and CD62L expression	X
In vitro transmigration across BBB	X
VZV-specific T-cell response	X
Immune phenotyping via flow cytometry	X	X	X

ISSN: 1471-2377